HLTH:LSE:LSE-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 208.625

Change

-1.30 (-0.62)%

Market Cap

N/A

Volume

40.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+1.00 (+0.45%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.95 (+0.69%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.02 (+0.11%)

USD 562.96B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.22 (+1.54%)

USD 562.96B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.05 (-0.08%)

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.02 (+0.06%)

USD 239.13B
0QZ3:LSE Qualcomm Inc.

+1.91 (+1.23%)

USD 202.26B
0R24:LSE Intel Corp.

+0.36 (+1.81%)

USD 196.14B

ETFs Containing HLTH:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.72% 43% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.72% 38% F 47% F
Trailing 12 Months  
Capital Gain 3.72% 43% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.72% 38% F 47% F
Trailing 5 Years  
Capital Gain 32.17% 60% D- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.17% 57% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 9.14% 59% D- 64% D
Dividend Return 9.14% 59% D- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.23% 76% C+ 87% B+
Risk Adjusted Return 111.12% 96% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike